*Movement Disorders Unit, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv; †Sackler School of Medicine, Tel Aviv University, Tel Aviv; ‡Tikun Olam, Research Department, Tel Aviv; §School of Public Health, Epidemiology, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv; ∥OneWorld Cannabis Ltd, Petah-Tikva; ¶Movement Disorders Center, Rabin Medical Center, Petah-Tikva; and #Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel.
Address correspondence and reprint requests to Tanya Gurevich, MD, Movement Disorders Unit, Tel Aviv Sourasky Medical Center, 6 Weizmann St, Tel Aviv 6423906, Israel; E-mail: [email protected]
Both Movement Disorders Units were responsible for patient with PD selection and providing the patient's telephone numbers. Tikun Olam Co was responsible for designing and administering the questionnaire, setting up the datasheet, and entering the data. The extraction and analysis of data and the report were performed by the first author (Y.B.). This article represents a final report on these data with the collaboration of all the authors.
Conflicts of Interest and Source of Funding: Lihi Bar-Lev Schleider is an employee of Tikun Olam Co, an Israel pharmaceutical company, which is developing cannabis-based medicinal extracts. Yehuda Baruch was a head of the Israeli Ministry of Health program for Medical Use of Cannabis in 2003 to 2012; at present, Yehuda Baruch is CSO of One World Cannabis Israel, which is a company dedicated to the research of cannabis and cannabinoids and their medical properties. All the other authors have nothing to declare.
